"Pakistan Introduces Groundbreaking Vaccine to Prevent Dog Bites"

KARACHI: Victims of dog bites can now access the 'Dow Rab' anti-rabies vaccine, developed by Dow University of Health Sciences, with just a phone call.

Professor Muhammad Saeed Qureshi, Vice-Chancellor of Dow University of Health Sciences, officially launched 'Dow Rab' during a ceremony. He announced that 30,000 doses of 'Dow Rab' have been dispatched through the distribution network. These doses are produced at Dow Institute of Life Sciences, Ojha campus, using imported raw materials.

Prof. Muhammad Saeed Qureshi emphasized his commitment to transitioning to locally sourced raw materials for anti-rabies vaccine production in Pakistan. Currently, the country relies on imported raw materials from China. Efforts are underway to manufacture an additional 170,000 doses of the vaccine domestically. It is anticipated that this objective will be successfully accomplished.
He noted that after years of rigorous research and navigating through the country's regulatory processes, Dow University commenced the commercial production of the anti-rabies vaccine at its Ojha campus. The complete course of the vaccine will be available for Rs. 1500.
It's worth recalling that during the COVID-19 pandemic, Dow University developed IVIG Immunoglobulin, which played a crucial role in saving the lives of hundreds of patients.
Previously, at another event, a memorandum of understanding was signed between Dow University and distributor network Miller & Phipps. The memorandum was signed by Registrar Dr. Ashar Afaq on behalf of Dow University. Miller & Phipps will ensure the phased availability of ARV Dow Rab throughout Pakistan.